Gastrointestinal cancer: Targeted therapies in gastric cancer - The dawn of a new era

Nature Reviews Clinical Oncology

Volumn 11, Issue 1, 2014, Pages 10-11

  Shah, Manish A ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CETUXIMAB; CISPLATIN; EPIRUBICIN; NEUROPILIN 1; ONARTUZUMAB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PERTUZUMAB; RAMUCIRUMAB; RILOTUMUMAB; TDM 1; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN A; MONOCLONAL ANTIBODY; VASCULOTROPIN RECEPTOR 2;

ESOPHAGEAL ADENOCARCINOMA; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; HUMAN; MOLECULARLY TARGETED THERAPY; MORBIDITY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; STOMACH ADENOCARCINOMA; STOMACH CANCER; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; CANCER STAGING; DISEASE COURSE; ESOPHAGEAL NEOPLASMS; FEMALE; LOWER ESOPHAGUS SPHINCTER; MALE; METHODOLOGY; PATHOLOGY; PROCEDURES; SURVIVAL;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; RESEARCH DESIGN; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84891041748     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2013.231     Document Type: Short Survey

References (9)

1. Fuchs, C. S. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet http://dx.doi.org/10.1016/S0140-6736(13)61719-5.
2. Jemal, A. et al. Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011).
3. Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687-697 (2010).
4. Lauren, P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at the histo-clinical classification. Acta Pathol. Microbiol. Scand. 64, 31-49 (1965).
5. Tan, I. B. et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 141, 476-485 (2011).
6. Shah, M. A. et al. Molecular classification of gastric cancer: a new paradigm. Clin. Cancer Res. 17, 2693-2701 (2011).
7. Yamada, Y. et al. Impact of dihydropyrimidine dehydrogenase status of biopsy specimens on efficacy of irinotecan plus cisplatin, S-1, or 5-FU as first-line treatment of advanced gastric cancer patients in JCOG9912 [abstract 4535]. J. Clin. Oncol. 27 (Suppl.), a4535 (2009).
8. Ohtsu, A. et al. Bevacizumab in combination with chemohterapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J. Clin. Oncol. 29, 3968-3976 (2011).
9. Van Cutsem, E. et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J. Clin. Oncol. 30, 2119-2127 (2012).